Volume 4, Issue 2, April 2017 ISSN: 2348-8565 (Online)
International Journal of Modern Engineering and Research Technology
Website: http://www.ijmert.org Email: editor.ijmert@gmail.com

Bioinformatics and Computational Technologies in Pharmacy: Emerging Applications and Future Directions

Bhanu Kumar Jain
Lecturer
Pharmacy
Kalalaniketn Polytechnic College
Jabalpur (M.P.), India
Email: jainbhaanukumar@gmail.com

Vaishali Jain
Lecturer
Department of Computer Science & Engineering
Govt. Women's Polytechnic College
Jabalpur (M.P.), India
Email:

ABSTRACT

Bioinformatics is an interdisciplinary field that integrates biology, computer science, mathematics, statistics, and information technology for the storage, retrieval, analysis, and interpretation of biological information. The rapid development of genomics, transcriptomics, proteomics, metabolomics, structural biology, and high-throughput screening has generated enormous quantities of biological and chemical data, creating an increasing need for computational approaches in pharmaceutical research. Bioinformatics is now involved in several stages of pharmaceutical development, including drug-target identification and validation, molecular modelling, computer-aided drug design, virtual screening, molecular docking, pharmacophore modelling, prediction of pharmacokinetic and toxicological properties, drug repurposing, pharmacogenomics, and personalized medicine. Bioinformatics also facilitates the integration of heterogeneous biological databases and supports the interpretation of large-scale molecular datasets.

The application of bioinformatics has contributed to a transition from conventional empirical drug discovery toward rational, target-based, and data-driven approaches. Computational methods can reduce the number of compounds requiring experimental evaluation, improve understanding of molecular mechanisms, and support prioritization of promising drug candidates. In pharmacogenomics, bioinformatics assists in identifying genetic variations associated with drug response and adverse drug reactions, thereby supporting individualized therapy. Furthermore, integration of bioinformatics with cheminformatics, computational chemistry, systems biology, and network pharmacology provides new opportunities for drug discovery and development .This review discusses the major applications, advantages, limitations, and future perspectives of bioinformatics in pharmacy with emphasis on literature.

Keywords:— *Bioinformatics, Drug Discovery, Computer-Aided Drug Design, Molecular Docking, Virtual Screening, Pharmacogenomics, Drug Repurposing, Molecular Modeling, Personalized Medicine.*

1. INTRODUCTION

The pharmaceutical sciences have undergone substantial transformation as a result of advances in molecular biology, genomics, computational science, and information technology. Traditional drug discovery has historically relied heavily on experimental screening, medicinal chemistry,

pharmacological testing, and repeated optimization. Although these approaches have produced numerous successful medicines, conventional drug development is generally lengthy, expensive, and associated with a high rate of failure [8,16]. The increasing availability of biological and chemical information has therefore encouraged the development of computational strategies capable of supporting different stages of pharmaceutical research [2].

Bioinformatics may broadly be defined as the application of computational, mathematical, and statistical techniques to the storage, retrieval, analysis, interpretation, and visualization of biological information. It is an interdisciplinary science involving molecular biology, genetics, biochemistry, computer science, mathematics, statistics, and information technology. Modern bioinformatics encompasses genomic and protein-sequence analysis, structural bioinformatics, systems biology, molecular modelling, data mining, pathway analysis, and integration of high-throughput biological datasets [1,17].

The importance of bioinformatics in pharmaceutical research has increased considerably with the availability of large biological databases and high-throughput technologies [6]. Genomic, transcriptomic, proteomic, and other molecular datasets can be compared between healthy and diseased states to identify molecular abnormalities, potential therapeutic targets, biomarkers, and mechanisms of disease [18,19]. Bioinformatics can subsequently assist in evaluating potential interactions between drug candidates and biological targets [2,20].

Xia emphasized that bioinformatics encompasses multiple areas, including genomics, transcriptomics, proteomics, population genetics, and molecular phylogenetics, and has applications throughout the drug-discovery process. Consequently, bioinformatics is not restricted to a single stage of pharmaceutical research but can contribute from early target identification through lead discovery, optimization, clinical development, and post-marketing research [21].

II. Bioinformatics and Pharmaceutical Sciences

The relationship between bioinformatics and pharmacy has developed through the increasing use of biological information in drug research. Pharmaceutical research requires an understanding of interactions among genes, proteins, receptors, enzymes, metabolites, pathways, and chemical compounds [14]. Bioinformatics provides computational methods for studying these complex relationships and integrating information from different biological and chemical sources [6,13].

Several major areas of pharmaceutical science benefit from bioinformatics, including drug-target identification, genomic and transcriptomic analysis, proteomic analysis, protein structure prediction, molecular modelling, molecular docking, virtual screening, pharmacophore modelling, QSAR analysis, pharmacogenomics, drug repurposing, biomarker discovery, ADMET prediction, and systems pharmacology [2,5,14].

The integration of these approaches has encouraged a more rational approach to pharmaceutical research. Instead of evaluating very large numbers of compounds experimentally without sufficient knowledge of their molecular targets, computational analysis can help prioritize compounds and biological targets before experimental validation [2,9].

III. Biological Databases and Their Role in Pharmacy

Biological databases represent one of the fundamental resources of bioinformatics. They provide organized collections of biological, chemical, structural, genomic, proteomic, pharmacological, and clinical information [6,17].

Genomic and nucleotide databases such as GenBank and RefSeq provide nucleotide and genomic sequence information that can be used to investigate genes associated with diseases, mutations, genetic variation, and potential drug targets [22]. Protein databases provide amino-acid sequences, functional annotations, structural information, domains, and protein-family relationships that are important for understanding potential pharmaceutical targets [23].

The Protein Data Bank (PDB) is a major resource containing experimentally determined three-dimensional structures of proteins, nucleic acids, and their complexes [24]. Structural information from such databases can be used in structure-based drug design, molecular docking, virtual screening, and molecular dynamics studies [2,24].

Chemical and drug databases provide information about chemical structures, molecular properties, biological activities, and drug-related information. These resources support ligand identification, similarity searching, virtual screening, and drug-repurposing studies [6,25].

The increasing integration of biological, chemical, and clinical information has created opportunities for computational methods to transform heterogeneous datasets into useful hypotheses for drug development [6,13].

IV. Role of Bioinformatics in Drug Discovery

Drug discovery is one of the most important applications of bioinformatics in pharmacy. Computational methods can contribute at several stages of the drug-discovery pipeline [2].

4.1 Identification of Drug Targets

Identification of an appropriate biological target is an essential early step in drug discovery. A drug target may be a receptor, enzyme, ion channel, transporter, nucleic acid, or other biological molecule involved in disease development [26].

Bioinformatics facilitates target identification through analysis of disease-associated genes, gene-expression profiles, mutations, protein-protein interactions, metabolic pathways, signalling networks, and comparative genomic information [18].

Comparison of molecular information between healthy and diseased tissues can identify genes and proteins associated with pathological conditions [18,27]. Such analysis may provide candidates for further experimental validation.

Bioinformatics approaches can therefore connect disease phenotypes with genetic mutations, altered gene expression, and other molecular factors [18]. These relationships can subsequently be used to identify targets capable of modifying disease-associated pathways [14].

4.2 Target Validation

Identification of a potential target does not necessarily establish that modifying the target will produce a therapeutic benefit. Target validation is therefore an essential component of drug discovery [26].

Bioinformatics can support target validation by examining conservation of the target across

species, expression patterns in normal and diseased tissues, biological pathway relationships, genetic evidence, protein-interaction networks, and phenotypes associated with target alterations [18].

Computational analysis can also identify relationships between a target and other biological molecules, thereby helping researchers evaluate whether modulation of a target could produce desirable or undesirable biological effects [14,28].

4.3 Protein Sequence and Structure Analysis

Proteins constitute important drug targets. Knowledge of their sequence and three-dimensional structure provides valuable information for drug design [23,24].

Bioinformatics tools can be used to analyze protein sequences, conserved domains, active sites, binding pockets, structural motifs, homologous proteins, and functional residues [17,23]. When an experimentally determined structure is unavailable, computational approaches such as homology modelling can provide structural models for further analysis [29].

Structural information can subsequently be used for molecular docking, virtual screening, and molecular dynamics studies [2,30].

V. COMPUTER-AIDED DRUG DESIGN

Computer-aided drug design (CADD) represents one of the most important intersections between bioinformatics, computational chemistry, medicinal chemistry, and pharmacy.

CADD approaches can broadly be divided into **structure**-based **drug design** and **ligand-based drug design**.

5.1 Structure-Based Drug Design

Structure-based drug design uses the three-dimensional structure of a biological target to identify or optimize compounds capable of interacting with the target [2,30].

Major techniques include molecular docking, molecular dynamics, binding-site analysis, and structure-based virtual screening.

Molecular docking attempts to predict the preferred orientation of a ligand within a target binding site and then estimate the strength or likelihood of the interaction [31]. Docking studies can provide information about hydrogen bonding, hydrophobic interactions, electrostatic interactions, aromatic interactions, and binding-site complementarity [31,32].

Virtual screening can subsequently be used to evaluate large chemical libraries computationally before experimental testing [33].

5.2 Ligand-Based Drug Design

Ligand-based methods are particularly useful when the three-dimensional structure of the target is unavailable but information about active compounds is known

Important approaches include molecular similarity searching, pharmacophore modelling, QSAR analysis, molecular fingerprints, and activity prediction [34].

Pharmacophore Modelling

A pharmacophore represents the essential steric and electronic features required for a molecule to interact with a biological target and produce a particular biological response .

Pharmacophore models may contain hydrogen-bond donors, hydrogen-bond acceptors, hydrophobic groups, aromatic rings, and positively or negatively ionizable groups . Pharmacophore-based screening can therefore

identify structurally diverse molecules possessing the essential features required for biological activity [35].

5.3 QSAR Analysis

Quantitative structure–activity relationship (QSAR) analysis attempts to establish mathematical relationships between chemical structure and biological activity [36].

A typical QSAR workflow involves:

Molecular descriptors may include molecular weight, lipophilicity, hydrogen-bonding properties, surface area, electronic parameters, and structural fingerprints

QSAR models can assist in predicting the activity of untested compounds and can guide structural modification during lead optimization [36,37].

VI. Virtual Screening

Virtual screening is a computational strategy for identifying potentially active molecules from large compound libraries . Instead of experimentally testing thousands or millions of compounds individually, computational filters can be applied to prioritize compounds for laboratory testing [33].

Two major approaches are structure-based virtual screening and ligand-based virtual screening

Structure-based virtual screening requires structural information about the biological target. Candidate compounds can be computationally docked against the target and ranked according to predicted interactions [31,33].

Ligand-based virtual screening uses known active compounds to identify molecules with similar structural or physicochemical characteristics [34].

Virtual screening can reduce the number of compounds requiring experimental evaluation and can therefore improve efficiency during early drug discovery [33].

VII. Bioinformatics in Lead Identification and Optimization

Once a potential hit compound has been identified, it generally undergoes optimization to improve potency, selectivity, pharmacokinetic properties, and safety [8,38].

Bioinformatics and computational approaches can assist by predicting relationships between structural modifications and biological activity. Computational analysis can help identify important structural features, predict target interactions, compare related compounds, identify possible off-target interactions, estimate physicochemical properties, and prioritize structural analogues .

The integration of bioinformatics with medicinal chemistry can therefore facilitate rational lead optimization and reduce unnecessary experimental synthesis and testing [38].

VIII. Pharmacogenomics and Personalized Medicine

Pharmacogenomics examines the influence of genetic variation on drug response . Genetic differences among individuals can influence drug absorption, distribution, metabolism, excretion, efficacy, and toxicity. Bioinformatics provides computational tools for analyzing genetic variation and connecting genomic information with drug response .

Important genes associated with drug response include **CYP2D6, CYP2C19, CYP2C9, TPMT, VKORC1, and SLCO1B1** [11,39].

Variations in these genes may influence the pharmacokinetics or pharmacodynamic response to particular medicines. Pharmacogenomic research therefore has the potential to improve drug selection and dosing while reducing adverse drug reactions.

Bioinformatics is particularly important because pharmacogenomics generates large datasets requiring computational analysis, annotation, comparison, and interpretation [10].

IX. Biomarker Discovery

Biomarkers are measurable biological characteristics that can provide information about disease, prognosis, treatment response, or toxicity .

Bioinformatics can facilitate biomarker discovery through analysis of gene expression, genetic mutations, protein expression, metabolite profiles, signalling pathways, and molecular networks

For example, genomic and transcriptomic datasets can be compared between diseased and healthy tissues to identify genes that are differentially expressed . Candidate biomarkers can subsequently be experimentally validated and potentially developed into diagnostic or companion diagnostic tools [18,40].

X. Bioinformatics in Proteomics

Proteomics involves the large-scale investigation of proteins expressed within a biological system . Proteomic studies can provide information concerning protein expression, post-translational modifications, protein-protein interactions, disease-associated proteins, drug-protein interactions, and signalling pathways .

Bioinformatics is essential for processing and interpreting proteomic datasets. Computational methods can identify proteins, compare expression levels, analyze protein networks, and identify pathways associated with disease.

Integration of proteomic information with genomic and transcriptomic data can provide a more comprehensive understanding of disease biology and drug action [41,42].

XI. Bioinformatics in Transcriptomics

Transcriptomics involves the comprehensive study of RNA transcripts within cells or tissues. Technologies such as microarrays and next-generation sequencing can generate large quantities of gene-expression information.

Bioinformatics can be used to process sequencing data, identify differentially expressed genes, analyze gene-expression patterns, identify disease-associated pathways, construct gene-regulatory networks, and compare treatment and control groups .

Transcriptomic information can contribute to target identification, biomarker discovery, mechanism-of-action studies, and evaluation of drug response [43,44].

XII. Systems Biology and Network Pharmacology

Many diseases are not caused by abnormalities in a single gene or protein but involve complex interactions among multiple biological pathways.

Systems biology uses computational approaches to study biological systems as interconnected networks. Network pharmacology extends this concept to drug action by examining relationships among drugs, targets, proteins, signalling pathways, cellular responses, and disease phenotypes .

Bioinformatics can integrate information concerning genes, proteins, pathways, drugs, and diseases to construct molecular networks. This approach is particularly valuable for understanding polypharmacology, drug

mechanisms, drug combinations, off-target effects, complex diseases, and drug resistance.

Hopkins proposed network pharmacology as an important paradigm for drug discovery because it considers the effects of drugs on interconnected biological networks rather than focusing exclusively on single drug-target relationships [14,28].

XIII. Bioinformatics in Drug Repurposing

Drug repurposing, or repositioning, involves identifying new therapeutic applications for existing drugs .

Because previously developed drugs may already possess substantial pharmacological and safety information, repurposing can potentially reduce some of the time and costs associated with developing completely new compounds.

Bioinformatics can facilitate drug repurposing by integrating drug-target databases, disease-gene associations, gene-expression signatures, protein-interaction networks, pathway information, pharmacological data, and chemical similarity information.

Computational approaches can identify unexpected relationships between existing drugs and disease-associated molecular pathways. Hodos et al. described computational drug repurposing as an approach that integrates biological, chemical, and clinical data to generate testable hypotheses for drug development [45-47].

XIV. Prediction of ADME and Toxicity

The pharmacological success of a drug depends not only on its activity against the intended target but also on its absorption, distribution, metabolism, excretion, and toxicity (ADMET) characteristics.

Computational approaches can assist in predicting intestinal permeability, solubility, plasma protein binding, tissue distribution, blood-brain barrier penetration, metabolic stability, cytochrome P450 interactions, renal clearance, transporter interactions, hepatotoxicity, cardiotoxicity, mutagenicity, and drug-drug interactions.

Early prediction of undesirable properties can help prioritize compounds with more favorable drug-like characteristics and reduce the likelihood of advancing compounds with serious liabilities [48,49].

XV. Bioinformatics in Drug–Drug Interaction Studies

Drug-drug interactions may occur when one medicine alters the pharmacokinetics or pharmacodynamics of another. Bioinformatics and computational pharmacology can assist in identifying possible interactions involving drug -metabolizing enzymes, transporters, receptors, and signalling pathways.

Analysis of molecular and pharmacological databases can help researchers identify potential interactions before extensive experimental investigation.Such computational approaches may be particularly useful during drug development and in pharmacovigilance research[50-51].

XVI. Role of Bioinformatics in Pharmaceutical Research Workflow

A simplified bioinformatics-assisted pharmaceutical research workflow can be represented as follows:



This workflow demonstrates that bioinformatics can support several interconnected stages rather than functioning as an isolated computational activity [2].

XVII. Advantages of Bioinformatics in Pharmacy

The major advantages of bioinformatics in pharmaceutical sciences include reduction in time, reduction in cost, improved target identification, rational drug design, improved understanding of drug mechanisms, support for personalized therapy, drug repurposing, and integration of large biological datasets [2,5].

Computational screening can evaluate large numbers of molecules rapidly and can reduce the number of compounds requiring laboratory testing. Genomic and proteomic analyses can identify previously unrecognized disease-associated targets. Similarly, structural information can facilitate rational design and optimization of compounds.

Bioinformatics also provides an important foundation for pharmacogenomics and personalized medicine by enabling researchers to analyze genetic variation and its relationship to drug response [10,11].

XVIII. Limitations and Challenges

Despite its substantial potential, bioinformatics has several limitations. Computational predictions depend strongly on the quality, completeness, and accuracy of the underlying datasets [6,17].

Biological systems are highly complex, and computational models may not completely reproduce cellular and physiological conditions [14]. Virtual screening and computational models can also produce false-positive predictions, meaning that compounds identified computationally may fail during experimental evaluation [2,33].

Consequently, computational predictions cannot replace experimental studies. Laboratory validation remains essential for establishing biological activity, pharmacological efficacy, and safety [2].

Another important challenge is the integration of heterogeneous datasets. Genomic, proteomic, chemical, clinical, and pharmacological datasets often differ in format, scale, and quality [6]. Effective pharmaceutical bioinformatics therefore requires collaboration among pharmacists, biologists, medicinal chemists, computational scientists, statisticians, and clinicians [13].

XIX. Conclusion

Bioinformatics has become an important component of modern pharmaceutical research. Its applications extend from biological database management and genomic analysis to drug-target identification, molecular modelling, virtual screening, pharmacophore development, QSAR analysis, pharmacogenomics, biomarker discovery, drug repurposing, and prediction of ADMET properties.

The major contribution of bioinformatics lies in its ability to convert large and complex biological datasets into meaningful information that can guide pharmaceutical research. By supporting target identification, lead discovery, optimization, and prediction of drug response, computational approaches can complement experimental research and potentially improve the efficiency of drug-development programs.

The integration of bioinformatics with medicinal chemistry, pharmacology, genomics, proteomics, systems biology, and clinical sciences represents an important direction for pharmaceutical research. Particularly, pharmacogenomics and molecular profiling provide opportunities for more individualized therapeutic strategies.

Nevertheless, computational predictions should be considered complementary to experimental evidence. The most effective pharmaceutical research strategy is therefore an integrated approach in which bioinformatics generates hypotheses and priorities that are subsequently tested through appropriate laboratory, preclinical, and clinical studies. In conclusion, bioinformatics has transformed the way biological and pharmaceutical information is collected, analyzed, and interpreted. Its continued integration with pharmaceutical sciences is expected to contribute to more rational drug discovery, improved therapeutic selection, reduced development costs, and ultimately more effective and safer medicines.

REFERENCES:

[1] Mount DW. *Bioinformatics: Sequence and Genome Analysis*. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2004.

[2] Sliwoski G, Kothiwale S, Meiler J, Lowe EW Jr. Computational methods in drug discovery. *Pharmacol Rev*. 2014;66(1):334–395.

[3] Ekins S, Mestres J, Testa B. In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. *Br J Pharmacol*. 2007;152(1):9–20.

[4] Lionta E, Spyrou G, Vassilatis DK, Cournia Z. Structure-based virtual screening for drug discovery: principles, applications and recent advances. *Curr Top Med Chem*. 2014;14(16):1923–1938.

[5] Hodos RA, Kidd BA, Khader S, Readhead BP, Dudley JT. Computational approaches to drug repurposing and pharmacology. Wiley *Interdiscip Rev SystBiol Med*. 2016;8 (3):186–210.

[6] Altman RB. Translational bioinformatics: linking the molecular world to the clinical world. *ClinPharmacolTher*. 2013;93(1):29–31.

[7] Chen R, Snyder M. Promise of personalized omics to precision medicine. *Wiley Interdiscip Rev SystBiol Med*. 2013;5(1):73–82.

[8] Jorgensen WL. The many roles of computation in drug discovery. *Science*. 2004;303(5665):1813–1818.

[9] Leelananda SP, Lindert S. Computational methods in drug discovery. *Beilstein J Org Chem*. 2016;12:2694–2718.

[10] Wen JG, Wu L, Pu XX, He FZ, Liu MZ, Zhou HH, Zhang W. Pharmacogenomics research: a potential strategy for drug development. *Pharmazie*. 2015;70 (7):437–445.

[11] Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. *Science*. 1999;286 (5439):487–491.

[12] McCarthy JJ, McLeod HL, Ginsburg GS. Genomic medicine: a decade of successes, challenges, and opportunities. *SciTransl Med*. 2013;5 (189):189sr4.

[13] Berger SI, Iyengar R. Network analyses in systems pharmacology. *Bioinformatics*. 2009;25(19):2466–2472.

[14] Hopkins AL. Network pharmacology: the next paradigm in drug discovery.

Nat Chem Biol. 2008;4(11):682–690.

[15] Csermely P, Korcsmáros T, Kiss HJM, London G, Nussinov R. Structure and dynamics of molecular networks: a novel paradigm of drug discovery. *PharmacolTher*. 2013;138 (3):333–408.

[16] Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. *Nat Rev Drug Discov*. 2004;3 (8):673–683.

[17] Baxevanis AD, Ouellette BFF, editors. *Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins*. 3rd ed. Hoboken: Wiley; 2005.

[18] Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. *Nat Rev ClinOncol*. 2011;8(3):184–187.

[19] Hamburg MA, Collins FS. The path to personalized medicine. *N Engl J Med*. 2010;363(4):301–304.

[20] Lounkine E, Keiser MJ, Whitebread S, et al. Large-scale prediction and analysis of drug activity at a molecular target. *Nature*. 2012;486 (7403):361–367.

[21] Pearl F, Harrison AP. Bioinformatics approaches to drug discovery. Literature available through 2016.

[22] Benson DA, Cavanaugh M, Clark K, et al. GenBank. *Nucleic Acids Res*. 2013;41(Database issue):D36–D42.

[23] UniProt Consortium. UniProt: a hub for protein information. *Nucleic Acids Res*. 2015;43(Database issue):D204–D212.

[24] Berman HM, Westbrook J, Feng Z, et al. The Protein Data Bank. *Nucleic Acids Res*. 2000;28(1):235–242.

[25] Wishart DS, Knox C, Guo AC, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. *Nucleic Acids Res*. 2008;36(Database issue):D901–D906.

[26] Hopkins AL, Groom CR. The druggable genome. *Nat Rev Drug Discov*. 2002;1(9):727–730.

[27] Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. *Nat Rev Genet*. 2011;12(1):56–68.

[28] Hopkins AL. Network pharmacology. *Nat Chem Biol*. 2008;4(11):682–690.

[29] Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: an automated protein homology-modeling server. *Nucleic Acids Res*. 2003;31(13):3381–3385.

[30] Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. *Nat Rev Drug Discov*. 2004;3(11):935–949.

[31] Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. *J Comput Chem*. 2009;30(16):2785–2791.

[32] Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. *CurrComput Aided Drug Des*. 2011;7(2):146–157.

[33] Shoichet BK. Virtual screening of chemical libraries. *Nature*. 2004;432 (7019):862–865.

[34] Bajorath J. Integration of virtual and high-throughput screening. *Nat Rev Drug Discov*. 2002;1(11):882–894.

[35] Yang SY. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. *Drug Discov Today*. 2010;15(11–12):444–450.

[36] Cherkasov A, Muratov EN, Fourches D, et al. QSAR modeling: where have you been? Where are you going to? *J Med Chem*. 2014;57(12):4977–5010.

[37] Hansch C, Leo A, Hoekman D. *Exploring QSAR: Fundamentals and Applications in Chemistry and Biology*. Washington, DC: American Chemical Society; 1995.

[38] Walters WP, Stahl MT, Murcko MA. Virtual screening—an overview. *Drug Discov Today*. 1998;3(4):160–178.

[39] Pirmohamed M. Pharmacogenomics: current status and future perspectives. *Br J ClinPharmacol*. 2011;72(3):347–356.

[40] Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. *ClinPharmacolTher*. 2001;69(3):89–95.

[41] Aebersold R, Mann M. Mass spectrometry-based proteomics. *Nature*. 2003;422(6928):198–207.

[42] Hanash S. Disease proteomics. *Nature*. 2003;422(6928):226–232.

[43] Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. *Nat Rev Genet*. 2009;10(1):57–63.

[44] Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. *Bioinformatics*. 2009;25(9):1105–1111.

[45] Ekins S, Williams AJ. Finding the new in the old: combinations of drugs and bioinformatics for drug repurposing. *ClinPharmacolTher*. 2011;90(2):157–160.

[46] Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. *Nat Rev Drug Discov*. 2004;3 (8):673–683.

[47] Ma DL, Chan DS, Leung CH. Drug repositioning by structure-based virtual screening. *ChemSoc Rev*. 2013;42(5):2130–2141.

[48] van de Waterbeemd H, Gifford E. ADMET in silico modelling: towards prediction paradise? *Nat Rev Drug Discov*. 2003;2(3):192–204.

[49] Ekins S, Waller CL, Swaan PW, Cruciani G, Wrighton SA, Wikel JH. Progress in computational toxicology. *J PharmacolExpTher*. 2003;305 (3):1116–1124.

[50] Ekins S, Wrighton SA. The role of CYP2B6 in human drug metabolism. *Drug MetabDispos*. 1999;27(9):1025–1032.

[51] Huang SM, Strong JM, Zhang L, et al. New era in drug interaction evaluation: US FDA perspective. ClinPharmacolTher. 2008;84(1):52–55.